267 results on '"Winters, Amanda"'
Search Results
2. Time to transplantation and pediatric acute myeloid leukemia outcomes
3. Targeting Acute Myeloid Leukemia Stem Cells Through Perturbation of Mitochondrial Calcium
4. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60
5. The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation
6. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
7. Emerging and Future Targeted Therapies for Pediatric Acute Myeloid Leukemia: Targeting the Leukemia Stem Cells
8. Targeting Acute Myeloid Leukemia Stem Cells Through Perturbation of Mitochondrial Calcium
9. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells
10. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia
11. The Feedback Loop Between Aboveground Herbivores and Soil Microbes via Deposition Processes
12. Development of a Socioecological Adolescent Sexual Health Index and Atlas: A Case Study in Washington State
13. CD123 CAR T cells for the treatment of myelodysplastic syndrome
14. Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis
15. Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy
16. Supplementary Table 6 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
17. Supplementary Table 2 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
18. Supplementary Table 8 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
19. Supplementary Tables 3-5 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
20. Supplementary Table 7 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
21. Supplementary Table 1 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
22. Supplementary Table 9 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
23. Supplementary Figures S1-S7 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
24. Data from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
25. POSTER: AML-219 Multi-Gene Molecular MRD by Digital PCR is Prognostic of Outcomes in AML Treated With Venetoclax/Azacitidine
26. AML-219 Multi-Gene Molecular MRD by Digital PCR is Prognostic of Outcomes in AML Treated With Venetoclax/Azacitidine
27. Molecular measurable residual disease: staring at red herrings
28. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia
29. A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
30. Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia
31. Identifying patterns of neurocognitive dysfunction through direct comparison of children with leukemia, central nervous system tumors, and sickle cell disease
32. Supplementary Figures S1-S5 from Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia
33. Supplementary Tables S1-S6 from Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia
34. Data from Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia
35. Responsible Gambling
36. Implementing Opt-Out HIV Testing in the Alameda County Jails
37. Digital polymerase chain reaction strategies for accurate and precise detection of vector copy number in chimeric antigen receptor T-cell products
38. The Feedback Loop Between Aboveground Herbivores and Soil Microbes via Deposition Processes
39. Time to transplantation and pediatric acute myeloid leukemia outcomes
40. A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy
41. Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study
42. Venetoclax in Combination with Tyrosine Kinase Inhibitors Demonstrates Efficacy in Preclinical Models of Ph+ Acute Lymphoblastic Leukemia
43. Identifying Patterns of Neurocognitive Dysfunction through Direct Comparison of Patients with Leukemia, CNS Tumors, and Sickle Cell Disease
44. Utilization of the Tapestri Platform for Quantification of Single Cell Vector Copy Number in CAR T Cell Products
45. EssentialSAT: A Space Systems Engineering Learning Laboratory
46. Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes
47. Sex and the Seminary: Preparing Ministers for Sexual Health and Justice
48. EPID-06. Transfusion related iron overload in pediatric patients with CNS tumors
49. N‐terminus DUX4‐immunohistochemistry is a reliable methodology for the diagnosis of DUX4‐fused B‐lymphoblastic leukemia/lymphoma (N‐terminus DUX4 IHC for DUX4‐fused B‐ALL)
50. Importance of clinical correlation in the diagnosis of pediatric B‐cell lymphomas
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.